Home/ Stocks/ HRMY

Harmony Biosciences Holdings, Inc. Common Stock

HRMY XNAS

$38.41 -0.34 (-0.88%) ▼ 15-min delayed

Open

$39.20

High

$39.43

Low

$38.20

Volume

994.5K

Market Cap

$2.26B

About Harmony Biosciences Holdings, Inc. Common Stock

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 293 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$261.28M	$75.43M	$1.30
Q1 2026	$215.39M	$32.49M	$0.56
FY 2025	$868.45M	$158.69M	$2.76
Q3 2025	$239.46M	$50.87M	$0.88

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 2, 2026

Calendar →

Related Market News

No specific coverage for HRMY yet. Check out our latest market news or earnings calendar.

Get HRMY Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Harmony Biosciences Holdings, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.